CA2353905C - Chemotherapeutic composition and method - Google Patents

Chemotherapeutic composition and method Download PDF

Info

Publication number
CA2353905C
CA2353905C CA2353905A CA2353905A CA2353905C CA 2353905 C CA2353905 C CA 2353905C CA 2353905 A CA2353905 A CA 2353905A CA 2353905 A CA2353905 A CA 2353905A CA 2353905 C CA2353905 C CA 2353905C
Authority
CA
Canada
Prior art keywords
mcc
dna
cells
cancer
chemotherapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2353905A
Other languages
English (en)
French (fr)
Other versions
CA2353905A1 (en
Inventor
Nigel C. Phillips
Mario C. Filion
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Telesta Therapeutics IP Inc
Original Assignee
Bioniche Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioniche Life Sciences Inc filed Critical Bioniche Life Sciences Inc
Publication of CA2353905A1 publication Critical patent/CA2353905A1/en
Application granted granted Critical
Publication of CA2353905C publication Critical patent/CA2353905C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2353905A 1998-12-04 1999-12-03 Chemotherapeutic composition and method Expired - Fee Related CA2353905C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11101998P 1998-12-04 1998-12-04
US60/111,019 1998-12-04
US12732099P 1999-04-01 1999-04-01
US60/127,320 1999-04-01
PCT/CA1999/001157 WO2000033875A1 (en) 1998-12-04 1999-12-03 Chemotherapeutic composition and method

Publications (2)

Publication Number Publication Date
CA2353905A1 CA2353905A1 (en) 2000-06-15
CA2353905C true CA2353905C (en) 2010-06-22

Family

ID=26808584

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2353905A Expired - Fee Related CA2353905C (en) 1998-12-04 1999-12-03 Chemotherapeutic composition and method

Country Status (11)

Country Link
EP (1) EP1135161B1 (https=)
JP (1) JP4380922B2 (https=)
AT (1) ATE276766T1 (https=)
AU (1) AU782335B2 (https=)
CA (1) CA2353905C (https=)
DE (1) DE69920506T2 (https=)
DK (1) DK1135161T3 (https=)
ES (1) ES2229792T3 (https=)
NZ (1) NZ511941A (https=)
PT (1) PT1135161E (https=)
WO (1) WO2000033875A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794368B1 (en) 1999-04-01 2004-09-21 Bioniche Life Sciences Inc. Composition and method for inducing apoptosis in prostate cancer cells
CA2395493C (en) 1999-12-28 2010-06-22 Bioniche Life Sciences Inc. Hyaluronic acid in the treatment of cancer
CN105943559A (zh) * 2010-10-13 2016-09-21 特莱斯塔治疗知识产权公司 细菌核糖核酸细胞壁组合物及其制备和使用方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100533576B1 (ko) * 1997-08-05 2005-12-05 바이오니취 라이프 사이언시즈 인코포레이티드 세포증식 및 세포사멸 조절용 조성물 및 방법

Also Published As

Publication number Publication date
AU782335B2 (en) 2005-07-21
WO2000033875A1 (en) 2000-06-15
ATE276766T1 (de) 2004-10-15
ES2229792T3 (es) 2005-04-16
AU1541200A (en) 2000-06-26
PT1135161E (pt) 2005-01-31
JP2002531524A (ja) 2002-09-24
DE69920506D1 (de) 2004-10-28
EP1135161A1 (en) 2001-09-26
JP4380922B2 (ja) 2009-12-09
NZ511941A (en) 2003-04-29
EP1135161B1 (en) 2004-09-22
CA2353905A1 (en) 2000-06-15
DE69920506T2 (de) 2005-10-13
DK1135161T3 (da) 2005-01-24

Similar Documents

Publication Publication Date Title
DE60036019T2 (de) Synthetische oligonukleotide die therapeutisch nützlich sind
JP2008208140A (ja) 細胞増殖および細胞死を調節する組成物および方法
US7662792B2 (en) Modulation of Fas and FasL expression
CA2353905C (en) Chemotherapeutic composition and method
US6809081B1 (en) Chemotherapeutic composition and method
JP4460220B2 (ja) オリゴヌクレオチド組成物、および細胞の分化を誘導するためのオリゴヌクレオチド組成物の使用
AU751667B2 (en) Composition and method for the treatment of bladder cancer
AU2002252891A1 (en) Oligonucleotide compositions and their use to induce differentiation of cells
JP2005509607A (ja) 治療的に有用なトリエチレングリコールコレステリルオリゴヌクレオチド
AU2001268863B2 (en) Modulation of FAS and FASL expression
ES2383671T3 (es) Modulación de la expresión de Fas y FasL por un oligonucleótido-fosfodiéster sintético y un anticuerpo anti-Fas
EP1165106A2 (en) Composition and method for inducing apoptosis in prostate cancer cells
EP1313853B1 (en) Modulation of fas and fasl expression by a synthetic phosphodiester oligonucleotide and an anti-fas antibody
WO2002018593A2 (en) Modulation of fas and fasl expression
AU2001268863A2 (en) Modulation of FAS and FASL expression
AU2001268863A1 (en) Modulation of FAS and FASL expression
MXPA00001272A (en) Composition and method for regulating cell proliferation and cell death

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20151203